Liver Transplant clinical trials at UCSD
7 in progress, 3 open to eligible people
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates
open to eligible people ages 18 years and up
This is a multi-center clinical trial in Cytomegalovirus (CMV) seronegative prospective liver transplant recipients to determine the efficacy of two doses of Cytomegalovirus-Modified Vaccinia Ankara (CMV-MVA) Triplex CMV vaccine pre-transplant. The primary objective is to assess the effect of pre-transplant (Tx) Triplex vaccination on duration of CMV antiviral therapy (AVT) within the first 100 days post-Tx in CMV seropositive donor (D+) and seronegative (R-) (D+R-) liver transplant recipients (LTxRs). A protocol-mandated preemptive therapy (PET) will be used for CMV disease prevention in D+R- LTxRs.
La Jolla, California and other locations
Resmetirom in Post-Liver Transplant Patients With MASH
open to eligible people ages 18-75
A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH. Cohort 2 will consist of subjects who have undergone liver transplant for indications other than MASH cirrhosis who developed de novo MASH.
La Jolla, California and other locations
US National OCS Liver Perfusion (OLP) Registry
open to all eligible people
This Registry is a sponsor-initiated, multi-center, observational, post-approval registry with an independent academic oversight. TransMedics has contracted with United Network for Organ Sharing (UNOS) the Federal manager of the U.S. national transplant outcomes registry to obtain data that is routinely collected by the Organ Procurement and Transplantation Network (OPTN) on all transplanted organs in the U.S. for both the OCS liver transplanted patients as well as patients transplanted using other preservation modalities. Additional data will be collected by participating centers using OCS Liver perfusion.
La Jolla, California and other locations
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
Sorry, not currently recruiting here
This is a study to determine the safety, efficacy, and tolerability of taking away the anti-rejection medicine, tacrolimus, in liver transplant recipients in conjunction with everolimus monotherapy to preserve renal function. Two hundred - seventy (270) subjects will be randomized 2:1 into one of two groups between 2-3 months post-transplant. Seventy participants will be placed into an observational group and will remain on their current post-transplant medications. The duration of the study from time of enrollment is 18-20 months.
San Diego, California and other locations
Seladelpar in Adult Liver Transplant Recipients With Ischemic Cholangiopathy (SELIC).
Sorry, not yet accepting patients
A prospective, open-label, single-arm, investigator-initiated study (SELIC) to evaluate the efficacy and safety of seladelpar in adult liver transplant recipients with Ischemic cholangiopathy (IC).
Global Utilization And Registry Database for Improved preservAtion of doNor Livers
Sorry, accepting new patients by invitation only
The objective of this registry is to collect and evaluate various clinical effectiveness parameters in patients with transplanted donor liver that were preserved and transported within the LIVERguard system, as well as retrospective standard of care patients
San Diego, California and other locations
OCS Liver Perfusion (OLP) Post-Approval Registry
Sorry, in progress, not accepting new patients
The objective of the OLP Registry is to collect more data on the post-transplant clinical outcomes of DBD and DCD donor livers preserved and assessed on OCS Liver System according to the approved indication and the OCS device performance in the real-world setting.
La Jolla, California and other locations
Our lead scientists for Liver Transplant research studies include Pranab Barman, MD Veeral Ajmera Gabriel Schnickel, MD, MPH.
Last updated: